DURECT Corporation (DRRX)
Sep 11, 2025 - DRRX was delisted (reason: acquired by BHC)
1.910
-0.020 (-1.04%)
Inactive · Last trade price on Sep 10, 2025

Company Description

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program.

The company’s lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis.

The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder.

It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited.

DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. As of September 11, 2025, DURECT Corporation operates as a subsidiary of Bausch Health Americas, Inc.

DURECT Corporation
DURECT logo
CountryUnited States
Founded1998
IPO DateSep 28, 2000
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees21
CEOJames Brown

Contact Details

Address:
10240 Bubb Road
Cupertino, California 95014-4166
United States
Phone408 777 1417
Websitedurect.com

Stock Details

Ticker SymbolDRRX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001082038
CUSIP Number266605104
ISIN NumberUS2666055007
Employer ID94-3297098
SIC Code2834

Key Executives

NamePosition
Dr. James E. Brown D.V.M.Co-Founder, Chief Executive Officer, President and Director
Timothy M. Papp M.B.A.Chief Financial Officer and Secretary
Dr. Norman L. Sussman M.D.Chief Medical Officer
Judy R. JoiceSenior Vice President of Operations and Corporate Quality Assurance
Steve Helmer J.D.Vice President and Chief Patent Counsel
Dr. WeiQi Lin M.D., Ph.D.Executive Vice President of Research and Development and Principal Scientist
Jian Li M.B.A.SVice President of Finance and Corporate Controller
Dr. Su Il Yum Ph.D.Executive Officer

Latest SEC Filings

DateTypeTitle
Sep 11, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Sep 11, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Sep 11, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Sep 11, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Sep 11, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Sep 11, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Sep 11, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Sep 11, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Sep 11, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Sep 11, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments